Inventor

KURAMOCHI TAICHI

JP33 patents

⚠️ This page may combine multiple inventors who share the name “KURAMOCHI TAICHI”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.

KURAMOCHI TAICHI

CHUGAI PHARMACEUTICAL CO LTD

Method of modifying isoelectric point of antibody via amino acid substitution in CDR

Method of modifying isoelectric point of antibody via amino acid substitution in CDR

Antigen-binding molecule containing modified Fc region

Antibody constant region variant

Therapeutic antigen-binding molecule with a FcRn-binding domain that promotes antigen clearance

Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use

Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use

Nucleic acids encoding anti-NR10 antibodies

Method of modifying isoelectric point of antibody via amino acid substitution in CDR

Method of modifying isoelectric point of antibody via amino acid substitution in CDR

Method for altering plasma retention and immunogenicity of antigen-binding molecule

Anti-myostatin antibodies, polypeptides containing variant Fc regions, and methods of use

Anti-myostatin antibodies and methods of use

Antigen-binding molecule having regulated conjugation between heavy-chain and light-chain

Humanized anti-epiregulin antibody, and cancer therapeutic agent comprising said antibody as active ingredient

Heterodimerized polypeptide

Antigen-binding molecule containing modified Fc region

Anti-myostatin antibodies and methods of use

Cytotoxicity-inducing therapeutic agent

Cytotoxicity-inducing therapeutic agent

Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use

Anti-C1S antibodies and methods of use

Polypeptide comprising aggrecan binding domain and carrying moiety

Modified Fc region of antibody

IGAWA TOMOYUKI

Method of modifying isoelectric point of antibody via amino acid substitution in CDR

Method for altering plasma retention and immunogenicity of antigen-binding molecule

Anti-glypican-3 antibody having improved kinetics in plasma

KURAMOCHI TAICHI

Antibody constant region variants with reduced Fcgammar binding

Anti-NR10 antibody and use thereof

Modified antibody constant regions

NEZU JUNICHI

Cytotoxicity-inducing therapeutic agent

MIMOTO FUTA

Heterodimerized polypeptide

MAEDA ATSUHIKO

Anti-AXL antibody